Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | CTSC | P53634 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL29201773 | 0.83 | CYP2C19 (0.44) | HSD11B1ALDH1A1MAPTGAACYP2C19 | |
| SCHEMBL6664040 | 0.81 | CTSC (0.36) | HSD11B1ALDH1A1MAPTMGAMSI | |
| SCHEMBL28708090 | 0.74 | TAAR1 (0.39) | HSD11B1ALDH1A1MAPTTAAR1CYP2C19 | |
| SCHEMBL30960368 | 0.73 | GRIN2B (0.44) | HSD11B1ALDH1A1MAPTGAATAAR1 | |
| SCHEMBL8285020 | 0.72 | HSD11B1 (0.47) | HSD11B1ALDH1A1MAPTGAAHPGD | |
| SCHEMBL6657473 | 0.70 | CTSC (0.35) | HSD11B1ALDH1A1MAPTMGAMSI | |
| SCHEMBL4021034 | 0.70 | HSD11B1 (0.39) | HSD11B1ALDH1A1MAPTGAACTSC | |
| SCHEMBL17033075 | 0.69 | HSD11B1 (0.43) | HSD11B1ALDH1A1MAPTTAAR1CYP2C19 | |
| SCHEMBL4904341 | 0.69 | GAA (0.52) | ALDH1A1MAPTGAAPOLB | |
| SCHEMBL14074888 | 0.68 | HSD11B1 (0.49) | HSD11B1ALDH1A1MAPTCYP2C19HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223746-B2 | Omega cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1438104-B1 | CO-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS | ALLERGAN INC (US) | 2006-04-05 | — | — | EP | disclosed |
| US-7022726-B2 | ω-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1442033-B1 | OMEGA-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS | ALLERGAN INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050113338-A1 | Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2005-05-26 | — | — | US | disclosed |
| CN-1617868-A | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN INC (US) | 2005-05-18 | — | — | CN | disclosed |
| EP-1442033-A1 | OMEGA-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS | Allergan, Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| EP-1438104-A1 | CO-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS | Allergan, Inc. (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040106580-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN INC. | 2004-06-03 | — | — | US | disclosed |
| US-6710072-B2 | VISION DEFECTS | ALLERGAN, INC. | 2004-03-23 | — | — | US | disclosed |
| US-20030130239-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6586462-B2 | ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2003-07-01 | — | — | US | disclosed |
| WO-2003040126-A1 | φ-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003037433-A1 | CO-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| US-20020187961-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2002-12-12 | — | — | US | disclosed |
| US-6376533-B1 | VISION DEFECTS | ALLERGAN SALES, INC. | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130239-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER2, PTGER4, PTGER1 | HSD11B1 390/4885ALDH1A1 1593/4885MAPT 4877/4885 |
| US-20020187961-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER2, PTGER1, PTGER3 | HSD11B1 337/4885ALDH1A1 1206/4885MAPT 4854/4885 |
| US-20050113338-A1 | Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER4, PTGER2, LTB4R2 | HSD11B1 321/4885ALDH1A1 2034/4885MAPT 4868/4885 |
| US-20040106580-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER2, PTGER4, PTGER1 | HSD11B1 391/4885ALDH1A1 1570/4885MAPT 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.